125 related articles for article (PubMed ID: 23898536)
1. [The expression of MGMT in pituitary adenomas and its association with tumour aggressiveness].
Jiang XB; Hu B; Fan X; He DS; Mao ZG; Chen M; Zhu YH; Wang HJ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 May; 44(3):462-5. PubMed ID: 23898536
[TBL] [Abstract][Full Text] [Related]
2. O-6-Methylguanine-DNA methyltransferase expression is associated with pituitary adenoma tumor recurrence: a systematic meta-analysis.
Dai C; Sun B; Liu X; Bao X; Feng M; Yao Y; Wei J; Deng K; Yang C; Li X; Ma W; Wang R
Oncotarget; 2017 Mar; 8(12):19674-19683. PubMed ID: 28152515
[TBL] [Abstract][Full Text] [Related]
3. MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
Micko ASG; Wöhrer A; Höftberger R; Vila G; Marosi C; Knosp E; Wolfsberger S
Pituitary; 2017 Dec; 20(6):643-653. PubMed ID: 28900805
[TBL] [Abstract][Full Text] [Related]
4. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.
Lau Q; Scheithauer B; Kovacs K; Horvath E; Syro LV; Lloyd R
Pituitary; 2010 Dec; 13(4):367-79. PubMed ID: 20740317
[TBL] [Abstract][Full Text] [Related]
5. MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.
Zuhur SS; Tanik C; Karaman Ö; Velet S; Çil E; Öztürk FY; Özkayalar H; Müslüman AM; Altuntaş Y
Endocrine; 2011 Oct; 40(2):222-7. PubMed ID: 21792693
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
7. O-methylguanine-DNA methyltransferase immunoexpression in a double pituitary adenoma: case report.
Mohammed S; Cusimano MD; Scheithauer BW; Rotondo F; Horvath E; Kovacs K
Neurosurgery; 2010 Feb; 66(2):E421-2; discussion E422. PubMed ID: 20087113
[TBL] [Abstract][Full Text] [Related]
8. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pituitary neoplasms with temozolomide: a review.
Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
[TBL] [Abstract][Full Text] [Related]
10. O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.
Salehi F; Scheithauer BW; Kovacs K; Horvath E; Syro LV; Sharma S; Manoranjan B; Cusimano M
Neurosurgery; 2012 Feb; 70(2):491-6; discussion 496. PubMed ID: 21822153
[TBL] [Abstract][Full Text] [Related]
11. MGMT expression in pituitary corticotroph adenomas and its relationship to clinical, pathological, and ultrastructural parameters in patients with Cushing's disease.
Witek P; Maksymowicz M; Szamotulska K; Piaścik A; Wojciechowska-Luźniak A; Stasiewicz A; Witek J; Zieliński G
Folia Neuropathol; 2020; 58(4):357-364. PubMed ID: 33480240
[TBL] [Abstract][Full Text] [Related]
12. MGMT expression and pituitary tumours: relationship to tumour biology.
McCormack A; Kaplan W; Gill AJ; Little N; Cook R; Robinson B; Clifton-Bligh R
Pituitary; 2013 Jun; 16(2):208-19. PubMed ID: 22797801
[TBL] [Abstract][Full Text] [Related]
13. MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications.
Kontogeorgos G; Thodou E; Koutourousiou M; Kaltsas G; Seretis A
Pituitary; 2019 Dec; 22(6):614-619. PubMed ID: 31571099
[TBL] [Abstract][Full Text] [Related]
14. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
Widhalm G; Wolfsberger S; Preusser M; Woehrer A; Kotter MR; Czech T; Marosi C; Knosp E
Cancer; 2009 Mar; 115(5):1070-80. PubMed ID: 19156926
[TBL] [Abstract][Full Text] [Related]
15. Unusual double pituitary adenoma: a case report.
Rotondo F; Khatun N; Scheithauer BW; Horvath E; Marotta TR; Cusimano M; Kovacs K
Pathol Int; 2011 Jan; 61(1):42-6. PubMed ID: 21166942
[TBL] [Abstract][Full Text] [Related]
16. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
McCormack AI; McDonald KL; Gill AJ; Clark SJ; Burt MG; Campbell KA; Braund WJ; Little NS; Cook RJ; Grossman AB; Robinson BG; Clifton-Bligh RJ
Clin Endocrinol (Oxf); 2009 Aug; 71(2):226-33. PubMed ID: 19067722
[TBL] [Abstract][Full Text] [Related]
17. Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Berinder K; Maiter D; Hoybye C; Ragnarsson O; Feldt-Rasmussen U; Krogh Rasmussen Å; van der Lely A; Petersson M; Johannsson G; Andersen M; Burman P
Endocrine; 2018 Dec; 62(3):737-739. PubMed ID: 30246233
[No Abstract] [Full Text] [Related]
18. Expression of additional transcription factors is of prognostic value for aggressive behavior of pituitary adenomas.
Micko A; Rötzer T; Hoftberger R; Vila G; Oberndorfer J; Frischer JM; Knosp E; Wolfsberger S
J Neurosurg; 2020 Apr; 134(3):1139-1146. PubMed ID: 32302984
[TBL] [Abstract][Full Text] [Related]
19. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.
Moshkin O; Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Uribe H; Gonzalez R; Cusimano M; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2011; 10(2):162-7. PubMed ID: 21724542
[TBL] [Abstract][Full Text] [Related]
20. Implications of MGMT methylation status in pituitary adenoma.
Arya S; Majaid MA; Shwetha SD; Sravani K; Arivazhagan A; Sampath S; Santosh V
Pathol Res Pract; 2014 Jul; 210(7):407-11. PubMed ID: 24690322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]